Table 3. Survival analysis.

		N	5-year OS(%)	Median (months)	p	5-year PFS(%)	Median (months)	p
Gender	Male	74	45.8	53.9	0.479	40.7	36.2	0.559
	Female	20	42.8	45.6		39.8	33.2
Age (years)	≤60	85	43.2	52.6	0.580	38.0	33.2	0.526
	>60	9	66.7	NA		66.7	76.6
Radiation	<50	24	45.2	53.9	0.858	43.4	44.3	0.200
Dose (Gy)	≥50	36	58.6	NA		67.3	NA
B symptoms	Absent	58	42.5	52.6	0.354	37.9	28.3	0.287
	Present	36	47.1	45.6		44.9	40.8
Waldeyer’s	Absent	74	47.5	54.2	0.712	43.1	33.5	0.675
ring	Present	20	39.7	52.6		31.5	36.2
Local	Absent	42	50.8	66.1	0.442	45.0	33.5	0.500
invasion	Present	52	38.7	45.6		36.0	36.2
LDH level	Normal	82	48.7	54.2	0.490	43.1	36.2	0.405
	Abnormal	12	0	33.7		0%	25.6
Ann Arbor	IE	72	57.5	129.4	0.000	49.9	49.0	0.000
stage	IIE	22	10.9	16.1		11.3	16.1
New staging	Limited IE	28	73.8	NA	0.000	63.6	76.6	0.000
	Extensive IE	44	44.0	53.9		38.9	40.8
	IIE	22	10.9	16.1		11.3	16.1
IPI score	0	71	47.4	56.8	0.885	41.9	61.6	0.842
	1	22	37.5	45.0		33.7	40.9
	2	1	0.0	12.0		0.0	12.0
ECOG performance	0-1	75	56.4	66.1	0.000	49.2	49.0	0.000
status	≥2	19	7.2	16.5		6.3	12.5
Initial	CT	66	37.7	37.4	0.048	30.1	28.8	0.038
treatment	RT	11	58.4	NA		24.2	14.0
	CCRT	17	70.6	NA		67.6	NA
Treatment	CT only	34	35.2	35.7	0.029	29.8	22.0	0.025
modalities	Combined therapy	43	41.9	52.6		36.0	33.5
	CCRT	17	70.6	NA		67.6	NA

NA: Not arrive.